Your browser doesn't support javascript.
loading
A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma.
Obr, Ales; Klener, Pavel; Furst, Tomas; Kriegova, Eva; Zemanova, Zuzana; Urbankova, Helena; Jirkuvova, Andrea; Petrackova, Anna; Malarikova, Diana; Forsterova, Kristina; Cudova, Barbora; Sedlarikova, Lenka; Berkova, Adela; Kasalova, Nela; Papajik, Tomas; Trneny, Marek.
Afiliação
  • Obr A; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
  • Klener P; First Department of Medicine - Hematology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Furst T; Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Kriegova E; Department of Mathematical Analysis and Application of Mathematics, Faculty of Science, Palacky University, Olomouc, Czech Republic.
  • Zemanova Z; Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
  • Urbankova H; Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Prague, Czech Republic.
  • Jirkuvova A; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
  • Petrackova A; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
  • Malarikova D; Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
  • Forsterova K; First Department of Medicine - Hematology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Cudova B; Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Sedlarikova L; First Department of Medicine - Hematology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Berkova A; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
  • Kasalova N; Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
  • Papajik T; Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Prague, Czech Republic.
  • Trneny M; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
Br J Haematol ; 191(5): e103-e106, 2020 12.
Article em En | MEDLINE | ID: mdl-32862455
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Proteína Supressora de Tumor p53 / Linfoma de Célula do Manto / Mutação Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: República Tcheca
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Proteína Supressora de Tumor p53 / Linfoma de Célula do Manto / Mutação Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: República Tcheca